This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, C.-S. Articles by Chen, C.-S. Search for Related Content PubMed PubMed Citation Articles by Chen, C.-S. Articles by Chen, C.-S.

Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation

¹ Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, Ohio; ² Department of Family Medicine, College of Medicine, National Taiwan University; ³ The Gerontology Research Division, The National Health Research Institutes, Taipei, Taiwan; and ⁴ Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio

Requests for reprints: Ching-Shih Chen, Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Parks Hall, 500 West 12th Avenue, Columbus, OH 43210. Phone: 614-688-4008; Fax: 614-688-8556; E-mail: chen.844{at}osu.edu.

This study reports a histone deacetylation-independent mechanism whereby histone deacetylase (HDAC) inhibitors sensitize prostate cancer cells to DNA-damaging agents by targeting Ku70 acetylation. Ku70 represents a crucial component of the nonhomologous end joining repair machinery for DNA double-strand breaks (DSB). Our data indicate that pretreatment of prostate cancer cells with HDAC inhibitors (trichostatin A, suberoylanilide hydroxamic acid, MS-275, and OSU-HDAC42) led to increased Ku70 acetylation accompanied by reduced DNA-binding affinity without disrupting the Ku70/Ku80 heterodimer formation. As evidenced by increased Ser¹³⁹-phosphorylated histone H2AX (H2AX), impaired Ku70 function diminished cellular capability to repair DNA DSBs induced by bleomycin, doxorubicin, and etoposide, thereby enhancing their cell-killing effect. This sensitizing effect was most prominent when cells were treated with HDAC inhibitors and DNA-damaging agents sequentially. Mimicking acetylation was done by replacing K282, K317, K331, K338, K539, or K542 with glutamine via site-directed mutagenesis, which combined with computer docking analysis was used to analyze the role of these lysine residues in the interactions of Ku70 with DNA broken ends. Mutagenesis of K282, K338, K539, or K542 suppressed the activity of Ku70 to bind DNA, whereas mutagenesis of K317 or K331 with glutamine had no significant effect. Moreover, overexpression of K282Q or K338Q rendered DU-145 cells more susceptible to the effect of DNA-damaging agents on H2AX formation and cell killing. Overall, the ability of HDAC inhibitors to regulate cellular ability to repair DNA damage by targeting Ku70 acetylation underlies the viability of their combination with DNA-damaging agents as a therapeutic strategy for prostate cancer. [Cancer Res 2007;67(11):5318–27]

This article has been cited by other articles:

				A. Y.J. Li, L. M. Boo, S.-Y. Wang, H. H. Lin, C. C.C. Wang, Y. Yen, B. P.C. Chen, D. J. Chen, and D. K. Ann Suppression of Nonhomologous End Joining Repair by Overexpression of HMGA2 Cancer Res., July 15, 2009; 69(14): 5699 - 5706. [Abstract] [Full Text] [PDF]

				R. L. Piekarz and S. E. Bates Epigenetic Modifiers: Basic Understanding and Clinical Development Clin. Cancer Res., June 15, 2009; 15(12): 3918 - 3926. [Abstract] [Full Text] [PDF]

				H. Yamaguchi, N. T. Woods, L. G. Piluso, H.-H. Lee, J. Chen, K. N. Bhalla, A. Monteiro, X. Liu, M.-C. Hung, and H.-G. Wang p53 Acetylation Is Crucial for Its Transcription-independent Proapoptotic Functions J. Biol. Chem., April 24, 2009; 284(17): 11171 - 11183. [Abstract] [Full Text] [PDF]

				G. Filomeni, G. Rotilio, and M. R. Ciriolo Molecular Transduction Mechanisms of the Redox Network Underlying the Antiproliferative Effects of Allyl Compounds from Garlic J. Nutr., November 1, 2008; 138(11): 2053 - 2057. [Abstract] [Full Text] [PDF]

				R. R. Rosato, J. A. Almenara, S. C. Maggio, S. Coe, P. Atadja, P. Dent, and S. Grant Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions Mol. Cancer Ther., October 1, 2008; 7(10): 3285 - 3297. [Abstract] [Full Text] [PDF]

				A. M. Sargeant, R. C. Rengel, S. K. Kulp, R. D. Klein, S. K. Clinton, Y.-C. Wang, and C.-S. Chen OSU-HDAC42, a Histone Deacetylase Inhibitor, Blocks Prostate Tumor Progression in the Transgenic Adenocarcinoma of the Mouse Prostate Model Cancer Res., May 15, 2008; 68(10): 3999 - 4009. [Abstract] [Full Text] [PDF]